Suzhou Basecare Medical (HKG:2170) saw its shares surge by nearly 10% on Wednesday after the company announced that it has obtained approval for the renewal of the registration certificate for its PGT-A kit from China's National Medical Products Administration.
The PGT-A kit is used for accurately detecting DNA abnormalities in embryos, and the renewed registration certificate is valid until February 20, 2030.
The positive regulatory development for one of the company's key products was welcomed by investors, driving the stock price higher on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments